Alector, Inc. (NASDAQ:ALEC) Given Average Recommendation of "Hold" by Analysts

Alector, Inc. (NASDAQ:ALEC - Get Free Report) has earned a consensus recommendation of "Hold" from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $3.50.

ALEC has been the topic of several research reports. HC Wainwright reissued a "buy" rating and set a $7.00 price objective on shares of Alector in a research note on Thursday, February 27th. Morgan Stanley reissued an "underweight" rating and set a $1.50 price objective (down previously from $3.00) on shares of Alector in a research note on Friday, March 7th.

Alector Stock Performance

Shares of NASDAQ ALEC traded up $0.07 during midday trading on Friday, hitting $1.20. 1,540,977 shares of the company traded hands, compared to its average volume of 797,265. Alector has a 12-month low of $0.87 and a 12-month high of $6.78. The stock has a 50-day moving average price of $1.27 and a 200 day moving average price of $2.31. The firm has a market cap of $118.90 million, a P/E ratio of -0.71 and a beta of 0.73.

Alector (NASDAQ:ALEC - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.59. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. The company had revenue of $54.24 million for the quarter, compared to analysts' expectations of $20.41 million. As a group, equities analysts expect that Alector will post -1.88 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ALEC. Squarepoint Ops LLC bought a new position in shares of Alector in the fourth quarter worth approximately $25,000. Tema Etfs LLC bought a new position in shares of Alector in the fourth quarter worth approximately $27,000. Tower Research Capital LLC TRC lifted its stake in shares of Alector by 71.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 14,670 shares of the company's stock worth $28,000 after buying an additional 6,096 shares in the last quarter. Vontobel Holding Ltd. lifted its stake in shares of Alector by 127.3% in the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company's stock worth $47,000 after buying an additional 14,000 shares in the last quarter. Finally, Apollon Wealth Management LLC bought a new position in shares of Alector in the fourth quarter worth approximately $47,000. Institutional investors own 85.83% of the company's stock.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.